Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting

Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting

Abstract T cell immunoglobulin domain and mucin domain-3 (TIM-3) is an important immune checkpoint (IC) protein in cancer immunosuppression that is considered a novel target for immunotherapy. Moreover, TIM-3, an immuno-myeloid regulator, is highly expressed on the cells of several solid tumors and...

Full description

Bibliographic Details
Main Authors: Jiaxiong Tan, Huo Tan, Yangqiu Li
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Experimental Hematology & Oncology
Subjects:
TIM-3
Gal-9
Immunotherapy
Hematological malignancies
Online Access:https://doi.org/10.1186/s40164-023-00421-2

Similar Items

Similar Items